Peptide Library / Detail
Vesugen
Half-life
Not extensively characterized; short peptides typically have half-lives of minutes to hours
Delivery
Oral administration or subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Vesugen is a short tripeptide (Lys-Glu-Asp / KED) derived from vascular tissues that acts as a bioregulatory peptide with geroprotective and vascular protective properties. Originally identified in research on endogenous growth regulation, it has been extensively studied for its effects on cellular aging, vascular health, and tissue regeneration. Vesugen functions as a epigenetic regulator that modulates gene expression in aging cells without altering DNA sequences.
Usage
Research protocols typically involve oral administration or subcutaneous injection of 0.1-1.0 mg per day for cycles of 10-20 days, repeated periodically (every 3-6 months). Studies have examined both continuous and intermittent dosing regimens. Clinical observations in elderly patients with polymorbidity used 20-day courses. Vesugen is often studied as part of peptide bioregulator combinations rather than as monotherapy.
Mechanism of Action
Vesugen (KED) acts as an epigenetic regulator by modulating chromatin structure and gene expression patterns in aging cells. It influences the transcriptional activity of genes involved in cellular senescence, vascular endothelial function, and extracellular matrix synthesis. Research demonstrates it upregulates genes associated with cell proliferation and tissue repair while downregulating senescence markers. In mesenchymal stem cells and fibroblasts, Vesugen normalizes age-related changes in gene expression profiles. Studies indicate it provides vasoprotective effects during atherosclerosis and restenosis by modulating vascular cell function and reducing pathological remodeling.
Benefits(8)
- Protects cells from age-related deterioration and senescence
- Promotes vascular health and may reduce atherosclerosis progression
- Modulates gene expression in aging fibroblasts and stem cells
- Supports neuronal differentiation and neurogenesis in aging models
- May improve work ability and functional capacity in elderly populations
- Demonstrates geroprotective effects in patients with chronic polymorbidity
- Enhances cellular repair mechanisms in vascular and connective tissues
- Normalizes expression of genes involved in extracellular matrix regulation
Side Effects(5)
- Minimal adverse effects reported in published clinical studies
- Generally well-tolerated in elderly populations with polymorbidity
- Specific adverse event profiles not extensively characterized in literature
- Long-term safety data beyond study durations limited
- Individual sensitivity to peptide formulations may vary